The second episode of CureTalks with Gary discusses new immunotherapies with Sellas Life Sciences. Talking to Gary Petersen is Dr Angelos M. Stergiou CEO and President of Sellas Life Sciences and Senior Advisor for Sellas, Dr. Nicholas J Sarlis.
Sellas Life Sciences is focused on the development of novel cancer immunotherapies for a broad range of cancer indications. Their Galinpepimut-S (GPS) is an engineered immunotherapy targeting the Wilms Tumor 1 (WT1) antigen. GPS has an ongoing Phase 3 trial for AML in patients achieving second complete remission. Sellas also has developed an HER-2 directed cancer immunotherapy (Nelipepimut-S) with potential for treatment of patients in the maintenance setting with triple-negative breast cancer. Take a deep dive with Gary on these life saving treatments in this episode.
#biotechcompanies #cancertreatments #immunotherapies #cancervaccine #innovation #breakthrough
SUBSCRIBE!
kzread.info?s...
LET'S CONNECT!
Website: https: www.curetalks.com/
Facebook: / curetalks
Instagram: / cure_talks_tx
Linkedin: www.linkedin.com/company/cure...
Twitter : / curetalks
Pinterest: / _saved